.Attribute Medicine, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin resulted in enhanced progression-free as well as total survival, causing FDA approval as well as a brand new treatment possibility for patients.